StageZero Life Sciences Ltd.
SZLS
Ранг среди акций
#36001
StageZero Life Sciences Ltd. is a vertically integrated healthcare enterprise... StageZero Life Sciences Ltd. is a vertically integrated healthcare enterprise specializing in the development and market release of advanced molecular diagnostic tests. These innovative solutions are designed for the proactive detection of diseases and individualized health management, with a particular emphasis on oncology-related conditions across North America. Central to its operations is the proprietary Sentinel Principle platform, which enables the identification of novel biomarkers directly from whole blood samples. Its flagship product, Aristotle, exemplifies this innovation; it's a comprehensive multi-cancer panel that simultaneously screens for numerous cancers from a single blood draw, boasting impressive sensitivity and specificity for each identified malignancy. Beyond Aristotle, the company's portfolio includes ColonSentry, a blood-based test gauging colorectal cancer risk; COVID-19 PCR testing and general blood analysis services; the Prostate Health Index for prostate cancer screening; and BreastSentry, designed to evaluate a woman's susceptibility to breast cancer. Established in 1998, StageZero Life Sciences Ltd. maintains its headquarters in Richmond Hill, Canada.
Цена акции
$0.02770208
Последняя синхронизация: 2025-03-10
Рыночная капитализация
$2.92M
Изменение (1 день)
-0.46%
Изменение (1 год)
443.18%
Страна
CA
Торговля StageZero Life Sciences Ltd. (SZLS)
Категория
Healthcare
Выручка компании StageZero Life Sciences Ltd. (SZLS)
Выручка на Oct 2026 TTM: 0
Согласно последним финансовым отчетам StageZero Life Sciences Ltd., текущая выручка компании (TTM) составляет 0. В 2026 году компания получила выручку 0 равна выручке в 2026 году, которая составила 0. Выручка — это общий доход, который компания получает от продажи товаров или услуг. В отличие от прибыли, расходы не вычитаются.
История выручки StageZero Life Sciences Ltd. с 2001 по 2026
Выручка на конец каждого года
| Год | Выручка | Изменить |
|---|---|---|
| 2022 | $3.80M | -25.12% |
| 2021 | $5.07M | 22.07% |
| 2020 | $4.15M | 2,893.29% |
| 2019 | $138.70K | -25.38% |
| 2018 | $185.87K | -54.85% |
| 2017 | $411.67K | -60.95% |
| 2016 | $1.05M | 223.54% |
| 2015 | $325.81K | -84.58% |
| 2014 | $2.11M | 1,602.71% |
| 2013 | $124.08K | -55.93% |
| 2012 | $281.56K | 185.17% |
| 2011 | $98.73K | -48.97% |
| 2010 | $193.48K | -82.32% |
| 2009 | $1.09M | -6.34% |
| 2008 | $1.17M | -46.62% |
| 2007 | $2.19M | -22.29% |
| 2006 | $2.82M | -38.72% |
| 2005 | $4.60M | 148.15% |
| 2004 | $1.85M | -36.24% |
| 2003 | $2.91M | 1,815.64% |
| 2002 | $151.65K | 23,315,859.41% |
| 2001 | $0.65 | 0.00% |
Выручка аналогичных компаний или конкурентов
| Компания | Выручка | Разница в выручке | Страна |
|---|---|---|---|
| $47.35B | - |
US
|
|
| $25.61B | - |
US
|
|
| $2.71B | - |
US
|
|
| - | - |
CN
|
|
| $7.37B | - |
US
|
